Skip to main content

Advertisement

Table 4 Results of the deterministic sensitivity analysis of posaconazole versus SAT in the prevention of IFI among high-risk neutropenic patients

From: Cost-effectiveness of posaconazole versusfluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain

Parameter Sensitivity analysis value ICER (cost per IFI avoided) ICER (cost per LYS)
Probability of IFI; Posaconazole 0.025 Dominant* Dominant*
  0.075 Dominant* Dominant*
Probability of IFI; SAT 0.075 Dominant* Dominant*
  0.15 Dominant* Dominant*
Probability of an IFI-related death; Posaconazole 0.2678 Dominant* Dominant*
  0.4464 Dominant* Dominant*
Probability of an IFI-related death; SAT 0.3636 Dominant* Dominant*
  0.6060 Dominant* Dominant*
Probability of death from other 0.1185 Dominant* Dominant*
causes; non IFI-related 0.1975 Dominant* Dominant*
Relative survival; AML 0.16 Dominant* Dominant*
  0.26 Dominant* Dominant*
Relative survival; MDS 0.06 Dominant* Dominant*
  0.10 Dominant* Dominant*
Total treatment cost per day; Posaconazole 77.77 Dominant* Dominant*
  129.61 Dominant* Dominant*
Total treatment cost per day; Fluconazole 12.70 Dominant* Dominant*
  21.16 Dominant* Dominant*
Total treatment cost† per day; Itraconazole 16.39 Dominant* Dominant*
  27.31 Dominant* Dominant*
Discount rate for costs and benefits 0% Dominant* Dominant*
  5% Dominant* Dominant*
  1. *Dominant strategy: posaconazole has lower cost and higher efficacy (measured as IFI avoided and LYS) compared to SAT (standard azole treatment: fluconazole/itraconazole)
  2. In euros at November 2009 prices